Helen Torley
Algemeen Directeur bij HALOZYME THERAPEUTICS, INC.
Vermogen: 26 M $ op 30-04-2024
Profiel
Helen I. Torley bekleedt de functie van President, Chief Executive Officer & Director bij Halozyme Therapeutics, Inc. Zij is ook lid van de raad van bestuur van Quest Diagnostics, Inc. en Director & Member-Health Section Governing Board bij Biotechnology Innovation Organization en lid van The Royal College of Physicians. In het verleden was zij Vice President & GM-United States Bone Health bij Amgen, Inc. en Chief Commercial Officer & Executive VP voor Onyx Pharmaceuticals, Inc. (een dochteronderneming van Amgen, Inc.), Vice President-Medical Affairs van Novartis, Inc., Vice President-Medical Affairs voor Sandoz SA en Vice President-Cardiovascular & Metabolic Sales bij Bristol-Myers Squibb World Wide Medicines Group. Zij heeft een bachelorgraad behaald aan de Universiteit van Glasgow.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 26-02-2024 | 676 744 ( 0.53% ) | 26 M $ | 30-04-2024 |
Actieve functies van Helen Torley
| Bedrijven | Functie | Begin |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Algemeen Directeur | 06-01-2014 |
| ANTARES PHARMA, INC. | Directeur/Bestuurslid | 24-05-2022 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Helen Torley
| Bedrijven | Functie | Einde |
|---|---|---|
| QUEST DIAGNOSTICS INCORPORATED | Directeur/Bestuurslid | 18-05-2022 |
| RELYPSA INC | Directeur/Bestuurslid | 01-09-2016 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Operationeel Directeur | 15-12-2011 |
| AMGEN INC. | Corporate Officer/Principal | 01-01-2011 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-01-2002 |
Opleiding van Helen Torley
| University of Glasgow | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| QUEST DIAGNOSTICS INCORPORATED | Health Services |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Antares Pharma, Inc.
 Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
| Sandoz SA |